Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex – A Placebo-Controlled Randomized Clinical Trial

RCT (n=224) reports cannabidiol significantly reduced tuberous sclerosis complex -associated seizures from baseline vs. placebo; reduction of 48.6% for the 25mg group, 47.5% for 50mg group vs. 26.5% for placebo; and 25mg/kg/day dose had better safety profile vs. 50-mg/kg/day.

Source:

JAMA Neurology